VeriMomrh-oligopeptide-1 hamilelikte güvenli mi?
No harmonised CLP classification (ECHA Annex VI) or SCCS/CIR reproductive safety restriction identified. However, as a peptide growth factor (EGF family) there is a theoretical class-based concern about mitogenic activity relevant to developing tissues; no animal or human reproductive toxicity data were identified to confirm hazard (sources searched: ECHA Annex VI, SCCS/CIR, PubMed, PubChem/CosIng, EWG). Topical systemic absorption for large peptides like rhEGF is expected to be negligible, so direct systemic exposure in pregnancy is unlikely.
Pregnancy-safe products containing rh-oligopeptide-1
Related ingredients
Frequently asked questions
- rh-oligopeptide-1 hamilelikte güvenli mi?
- No harmonised CLP classification (ECHA Annex VI) or SCCS/CIR reproductive safety restriction identified. However, as a peptide growth factor (EGF family) there is a theoretical class-based concern about mitogenic activity relevant to developing tissues; no animal or human reproductive toxicity data were identified to confirm hazard (sources searched: ECHA Annex VI, SCCS/CIR, PubMed, PubChem/CosIng, EWG). Topical systemic absorption for large peptides like rhEGF is expected to be negligible, so direct systemic exposure in pregnancy is unlikely.
- rh-oligopeptide-1 emzirirken güvenli mi?
- Same rationale as pregnancy: theoretical concern from growth-factor activity if systemically absorbed, but no evidence of reproductive or lactation-specific toxicity or breast milk transfer. Large peptide size and available topical formulations suggest negligible systemic bioavailability after topical cosmetic use (sources: PubMed, PubChem, CosIng, EWG).
- rh-oligopeptide-1 bebek cildi için güvenli mi?
- Hazard and mechanism scores unchanged (no infant-specific data showing reproductive/ developmental toxicity). Exposure score increased by +1 because infant skin has a less mature barrier and higher surface-area-to-weight ratio; if the peptide has any measurable percutaneous uptake the relative exposure in 0–3 yr olds would be higher. No studies demonstrating placental/breastmilk transfer or infant adverse outcomes were found (sources: PubMed, CosIng, PubChem, EWG).
- VeriMom rh-oligopeptide-1 nasıl puanlıyor?
- VeriMom rh-oligopeptide-1'yi EU CosIng, ECHA sınıflandırmaları ve PubMed çalışmalarına göre 73/100 (düşük risk) olarak puanlar.
- Hamilelikte rh-oligopeptide-1 yerine neler kullanılabilir?
- Benzer işlevli ve bilinen riski olmayan alternatifleri içeren listemize bakın.
Her etiketi 2 saniyede kontrol et
VeriMom'u ücretsiz indirin — herhangi bir ürünü tarayın ve hamilelik güvenlik puanını anında görün.
Tıbbi Sorumluluk Reddi
Bu bilgiler yalnızca eğitim amaçlıdır ve tıbbi tavsiye niteliği taşımaz. Güvenlik puanları kamuya açık verilere dayanmaktadır ve tüm riskleri yansıtmayabilir. Hamilelik veya emzirme döneminde herhangi bir ürünü kullanmadan önce her zaman sağlık uzmanınıza danışın.